Anticoagulation Management after Endoscopy

Introduction to Resumption Guidelines

• The American Society for Gastrointestinal Endoscopy and other guideline societies, including the American Gastroenterological Association, recommend resuming anticoagulation therapy, such as apixaban (Eliquis), 24-72 hours after endoscopy, depending on bleeding and thrombotic risks, in patients with a history of atrial fibrillation or venous thromboembolism 1, 2, 3
• The resumption timeframe may vary based on the specific procedure, patient's individual risks, and guideline society recommendations, with a general range of 24-48 hours for low-risk procedures like colonoscopy with biopsy, and 48-72 hours for higher-risk procedures or patients with moderate to severe renal impairment 1, 2, 3, 4

Bleeding and Thrombotic Risk Assessment

• Patients with high thrombotic risk, including those with mechanical heart valves or recent stroke, should resume anticoagulation at the earlier timeframe of 24 hours, if hemostasis is adequate, to minimize the risk of thrombotic events, as recommended by the Asian Pacific guidelines 1, 2
• Patients with low thrombotic risk, such as those with atrial fibrillation without high-risk factors, can resume anticoagulation at the later timeframe of 48 hours, if hemostasis is adequate, balancing the risks of bleeding and thrombosis, as suggested by the European/British guidelines 1, 2, 3
• The following table summarizes the recommended resumption timeframes based on thrombotic risk:

2, 3

Management of Anticoagulation

• Confirming adequate hemostasis before restarting anticoagulation is crucial to prevent bleeding complications, and patients should be monitored for signs of active bleeding, such as hematemesis or melena 1
• Unlike warfarin, bridging anticoagulation is not recommended when restarting direct oral anticoagulants like apixaban, due to their rapid onset of action, which makes bridging unnecessary and may increase bleeding risk, as stated by the Asian Pacific guidelines and supported by other sources 2, 4
• Monitoring for signs of delayed bleeding for 2 weeks after resuming anticoagulation is essential, and patients should be alert for symptoms such as black stools, dizziness, or abdominal pain 1

Special Considerations

• Patients with both high bleeding and high thrombotic risks may require consultation with a hematologist or cardiologist to determine the optimal timing for resumption, as suggested by the European/British guidelines 3
• Patients with moderate to severe renal impairment (CrCl <50 mL/min) may require extended resumption times, although this is based on a guideline from Praxis Medical Insights, a less preferred source 4
• The following patient populations may require individualized consideration: 1, 2, 3, 4